Liraglutide Effectiveness in Type 2 Diabetes

Bibliographic Details
Main Author: Silva-Nunes, José
Publication Date: 2022
Other Authors: Nascimento, Edite, Louro, Joana, Dores, Jorge, Laginha, Teresa, Gonçalves-Ferreira, Ana, Alves, Marta, Souto, Selma B., Cunha, Nelson, Pina, Elsa, Duarte, Rui, Raposo, João Filipe
Format: Article
Language: eng
Source: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
Download full: http://hdl.handle.net/10362/150945
Summary: Funding Information: This study was promoted by the Portuguese Society of Diabetology (SPD) with the sponsorship of Novo Nordisk Portugal, Lda. Statistical analysis and medical writing were conducted by W4Research with the funding of Novo Nordisk Portugal, Lda. The study was conducted by the SPD, with no influence from the sponsor. Publisher Copyright: © 2022 by the authors.
id RCAP_91dc863cbbbb2583167040d98d733df8
oai_identifier_str oai:run.unl.pt:10362/150945
network_acronym_str RCAP
network_name_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository_id_str https://opendoar.ac.uk/repository/7160
spelling Liraglutide Effectiveness in Type 2 DiabetesInsights from a Real-World Cohort of Portuguese Patientsanthropometric parameterscardiovascular risk factorsglycaemic controlliraglutidereal-world evidencetype 2 diabetesEndocrinology, Diabetes and MetabolismBiochemistryMolecular BiologySDG 3 - Good Health and Well-beingFunding Information: This study was promoted by the Portuguese Society of Diabetology (SPD) with the sponsorship of Novo Nordisk Portugal, Lda. Statistical analysis and medical writing were conducted by W4Research with the funding of Novo Nordisk Portugal, Lda. The study was conducted by the SPD, with no influence from the sponsor. Publisher Copyright: © 2022 by the authors.Liraglutide is a long-acting glucagon-like peptide-1 receptor agonist prescribed to diabetic patients for glycaemic control. To understand the impact of liraglutide in the real-world setting, this study analysed its effects in a Portuguese cohort of Type 2 diabetes patients. This was an observational, multicentric, and retrospective study that included 191 liraglutide-treated patients with at least 12 months of treatment. Patients’ data were collected and analysed during a 24-month follow-up period. Overall, liraglutide treatment effectively reduced HbA1c levels from 8.3% to around 7.5%, after 6, 12, and 24 months (p < 0.001). In fact, 38.2%, 37.2%, and 44.8% of patients at 6, 12, and 24 months, respectively, experienced an HbA1c reduction of at least 1%. Moreover, a persistent reduction in anthropometric features was also observed, with 44.0%, 47.6%, and 54.4% of patients achieving a weight reduction of at least 3% at 6, 12, and 24 months, respectively. Finally, significant improvements were observed in the HDL-c and LDL-c levels. Our results demonstrate that liraglutide effectively promoted the reduction of HbA1c values during routine clinical practice, which was sustained throughout the study. In addition, there were significant improvements in anthropometric parameters and other cardiovascular risk factors.NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)RUNSilva-Nunes, JoséNascimento, EditeLouro, JoanaDores, JorgeLaginha, TeresaGonçalves-Ferreira, AnaAlves, MartaSouto, Selma B.Cunha, NelsonPina, ElsaDuarte, RuiRaposo, João Filipe2023-03-20T22:22:34Z2022-112022-11-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10362/150945eng2218-1989PURE: 56419425https://doi.org/10.3390/metabo12111121info:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2024-05-22T18:10:21Zoai:run.unl.pt:10362/150945Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-28T17:40:51.099699Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse
dc.title.none.fl_str_mv Liraglutide Effectiveness in Type 2 Diabetes
Insights from a Real-World Cohort of Portuguese Patients
title Liraglutide Effectiveness in Type 2 Diabetes
spellingShingle Liraglutide Effectiveness in Type 2 Diabetes
Silva-Nunes, José
anthropometric parameters
cardiovascular risk factors
glycaemic control
liraglutide
real-world evidence
type 2 diabetes
Endocrinology, Diabetes and Metabolism
Biochemistry
Molecular Biology
SDG 3 - Good Health and Well-being
title_short Liraglutide Effectiveness in Type 2 Diabetes
title_full Liraglutide Effectiveness in Type 2 Diabetes
title_fullStr Liraglutide Effectiveness in Type 2 Diabetes
title_full_unstemmed Liraglutide Effectiveness in Type 2 Diabetes
title_sort Liraglutide Effectiveness in Type 2 Diabetes
author Silva-Nunes, José
author_facet Silva-Nunes, José
Nascimento, Edite
Louro, Joana
Dores, Jorge
Laginha, Teresa
Gonçalves-Ferreira, Ana
Alves, Marta
Souto, Selma B.
Cunha, Nelson
Pina, Elsa
Duarte, Rui
Raposo, João Filipe
author_role author
author2 Nascimento, Edite
Louro, Joana
Dores, Jorge
Laginha, Teresa
Gonçalves-Ferreira, Ana
Alves, Marta
Souto, Selma B.
Cunha, Nelson
Pina, Elsa
Duarte, Rui
Raposo, João Filipe
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
RUN
dc.contributor.author.fl_str_mv Silva-Nunes, José
Nascimento, Edite
Louro, Joana
Dores, Jorge
Laginha, Teresa
Gonçalves-Ferreira, Ana
Alves, Marta
Souto, Selma B.
Cunha, Nelson
Pina, Elsa
Duarte, Rui
Raposo, João Filipe
dc.subject.por.fl_str_mv anthropometric parameters
cardiovascular risk factors
glycaemic control
liraglutide
real-world evidence
type 2 diabetes
Endocrinology, Diabetes and Metabolism
Biochemistry
Molecular Biology
SDG 3 - Good Health and Well-being
topic anthropometric parameters
cardiovascular risk factors
glycaemic control
liraglutide
real-world evidence
type 2 diabetes
Endocrinology, Diabetes and Metabolism
Biochemistry
Molecular Biology
SDG 3 - Good Health and Well-being
description Funding Information: This study was promoted by the Portuguese Society of Diabetology (SPD) with the sponsorship of Novo Nordisk Portugal, Lda. Statistical analysis and medical writing were conducted by W4Research with the funding of Novo Nordisk Portugal, Lda. The study was conducted by the SPD, with no influence from the sponsor. Publisher Copyright: © 2022 by the authors.
publishDate 2022
dc.date.none.fl_str_mv 2022-11
2022-11-01T00:00:00Z
2023-03-20T22:22:34Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10362/150945
url http://hdl.handle.net/10362/150945
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 2218-1989
PURE: 56419425
https://doi.org/10.3390/metabo12111121
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron:RCAAP
instname_str FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron_str RCAAP
institution RCAAP
reponame_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
collection Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository.name.fl_str_mv Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
repository.mail.fl_str_mv info@rcaap.pt
_version_ 1833596884303740928

Similar Items